| Protocol No. | 115523 | Principal Investigator | Friedlander, Terence |
| Phase | II (Cancer Control) |
| Age Group | Adult | Scope | National |
| Secondary Protocol No. | ARN509-002 |
| Title | The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer |
| Objective | 1. To compare the mean change in QOL as measured by total FACT-P score after 12 months of therapy with ARN-509 monotherapy compared with LHRHa monotherapy
2. To compare the mean change in QOL as measured by total FACT-P score after 12 months of therapy of ARN-509 + LHRHa vs. LHRHa monotherapy
|
|
|
| Key Eligibility | Age: 18+
* Male
* Histologically proven adenocarcinoma of the prostate
* No history of seizures or medical conditions which may lower seizure threshold |
| Applicable Disease Sites | Prostate |
|
|
| Drugs Involved | ARN-509 |
| Status | Open |
| Participating Institutions | Mt. Zion : Rebecca Cook |
|
| Eligibility Document | 115523_CTGovEligibility_NCT01790126.doc |
|
| Contact | Rebecca Cook |
Phone:415-885-3557
Pager:
Email:CookR@cc.ucsf.edu |